Skip to main content
Clinical Trials/NCT06743321
NCT06743321
Not yet recruiting
Not Applicable

A Prospective Study of the Effectiveness of Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients

Peking Union Medical College Hospital2 sites in 1 country234 target enrollmentAugust 1, 2026

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Critical Care Nursing
Sponsor
Peking Union Medical College Hospital
Enrollment
234
Locations
2
Primary Endpoint
ICU-acquired anxiety
Status
Not yet recruiting
Last Updated
last month

Overview

Brief Summary

The goal of this clinical trial is to learn the effect of Speech-to-speech Voice-Cloning Care (SVCC) on improving ICU-acquired anxiety for critically ill patients. The main question it aims to answer is:

  • Can the use of participants' loved ones' voices by nurses in communication while providing care lead to better mental health and clinical outcomes?

Researchers will see if the implementation of SVCC can reduce anxiety and depression and improve clinical outcomes.

Participants will:

  • Receive the SVCC intervention until the endotracheal tube (ETT) is removed.
  • Keep a diary of delirium, the duration of mechanical ventilation, and ICU stays.

Detailed Description

During the SVCC, healthcare will be delivered by nurses who will communicate with participants using the familiar voices of their loved ones, transformed in real-time by an artificial intelligence voice-cloning tool.

Registry
clinicaltrials.gov
Start Date
August 1, 2026
End Date
December 31, 2027
Last Updated
last month
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Expected mechanical ventilation time \> 24 hours;
  • Expected ICU stay \> 72 hours;
  • Language: Chinese;
  • Richmond Agitation-Sedation Scale (RAAS) score ≥ -2 points;
  • Hemodynamic stability.

Exclusion Criteria

  • Severe hearing impairment or worse (Grade 3 or higher according to WHO's Grades of hearing impairment);
  • Disorders of consciousness or comprehension;
  • Mental or psychological disorders that are being treated with medication;
  • Head trauma or surgery resulting in an inability to wear earphones.

Outcomes

Primary Outcomes

ICU-acquired anxiety

Time Frame: Baseline (Day 0); daily from ICU admission through ICU discharge (an average of 7 days); and 3 days post-ICU discharge.

The primary outcome assessment will be conducted using the Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A). The HADS is used to assess symptoms of anxiety and depression in medical patients, which includes two subscales: one for anxiety (HADS-A) and one for depression (HADS-D). Each subscale consists of seven items, with scores for each item ranging from 1 to 4. The total score for each subscale ranges from 7 to 28, with a score of 11 or above considered to be the critical value.

Secondary Outcomes

  • ICU-acquired depression(Baseline (Day 0); daily from ICU admission through ICU discharge (an average of 7 days); and 3 days post-ICU discharge.)
  • Incidence of Delirium(Twice daily from Day 1 through ICU discharge, an average of 7 days.)
  • Duration of Mechanical Ventilation(From the start of mechanical ventilation through endotracheal tube (ETT) removal, an average of 6 days.)
  • ICU Stay(From ICU admission through ICU discharge, an average of 7 days.)
  • Qualitative assessment(Once during the follow-up visit, three days after the participant is discharged from the ICU.)

Study Sites (2)

Loading locations...

Similar Trials